Jun 08, 2021 / 02:00PM GMT
Operator
Ladies and gentlemen, welcome to Roche's virtual event on key oncology data presented at 2021 ASCO annual meeting. My name is Henrik and I am the technical operator for today's call. Kindly note that the webinar is being recorded. (Operator Instructions)
At this time, it's my pleasure to introduce you to Karl Mahler, Head of Investor Relations and Group Planning. Karl, the stage is yours.
Karl Mahler - Roche Holding AG - Head of IR
Yes. Thanks a lot, Henrik. Welcome to our fourth science call this year. We have reserved 1.5 hours. So half of the time will be for Q&A and half of the time for presentation. So we all are some experts in the meantime, as I know. (Operator Instructions) So very much looking forward to an interactive event.
For this year's ASCO, we have chosen a bit different format, I have to say. So first, we will focus on exciting data presented at this year's ASCO for obvious reasons like the IMpower010 or any kind of updates on the bispecifics. Second is, we also wanted to give you an update on our exciting programs in
Roche Holding AG Virtual Event on Key Oncology Data Presented at 2021 ASCO Annual Meeting Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot